pdufa.bio
CalendarConferencesAdCommDecisionsReadoutsResearchAccount
Home › PDUFA Calendar › NUVL

NUVL FDA calendar & decision history

Nuvalent Inc. · 2 upcoming · 0 past FDA decisions

Upcoming FDA catalysts

NUVL · Sep 18, 2026Zidesamtinib (NVL-520) - (ARROS-1) — ROS1 Non-small cell lung cancer (NSCLC)NUVL · Nov 27, 2026Neladalkib (NVL-655) - (ALKOVE-1) — TKI-pretreated ALK-positive NSCLC
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates NUVL's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.